1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global End-Stage Kidney Disease Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027 1.2.2 MK-3866 1.2.3 Pacritinib 1.2.4 Sanguinate 1.2.5 Tesidolumab 1.2.6 Others 1.3 Market by Application 1.3.1 Global End-Stage Kidney Disease Treatment Market Share by Application: 2016 VS 2021 VS 2027 1.3.2 Clinic 1.3.3 Hospital 1.3.4 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global End-Stage Kidney Disease Treatment Market Perspective (2016-2027) 2.2 End-Stage Kidney Disease Treatment Growth Trends by Regions 2.2.1 End-Stage Kidney Disease Treatment Market Size by Regions: 2016 VS 2021 VS 2027 2.2.2 End-Stage Kidney Disease Treatment Historic Market Share by Regions (2016-2021) 2.2.3 End-Stage Kidney Disease Treatment Forecasted Market Size by Regions (2022-2027) 2.3 End-Stage Kidney Disease Treatment Industry Dynamic 2.3.1 End-Stage Kidney Disease Treatment Market Trends 2.3.2 End-Stage Kidney Disease Treatment Market Drivers 2.3.3 End-Stage Kidney Disease Treatment Market Challenges 2.3.4 End-Stage Kidney Disease Treatment Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top End-Stage Kidney Disease Treatment Players by Revenue 3.1.1 Global Top End-Stage Kidney Disease Treatment Players by Revenue (2016-2021) 3.1.2 Global End-Stage Kidney Disease Treatment Revenue Market Share by Players (2016-2021) 3.2 Global End-Stage Kidney Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by End-Stage Kidney Disease Treatment Revenue 3.4 Global End-Stage Kidney Disease Treatment Market Concentration Ratio 3.4.1 Global End-Stage Kidney Disease Treatment Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by End-Stage Kidney Disease Treatment Revenue in 2020 3.5 End-Stage Kidney Disease Treatment Key Players Head office and Area Served 3.6 Key Players End-Stage Kidney Disease Treatment Product Solution and Service 3.7 Date of Enter into End-Stage Kidney Disease Treatment Market 3.8 Mergers & Acquisitions, Expansion Plans 4 End-Stage Kidney Disease Treatment Breakdown Data by Type 4.1 Global End-Stage Kidney Disease Treatment Historic Market Size by Type (2016-2021) 4.2 Global End-Stage Kidney Disease Treatment Forecasted Market Size by Type (2022-2027) 5 End-Stage Kidney Disease Treatment Breakdown Data by Application 5.1 Global End-Stage Kidney Disease Treatment Historic Market Size by Application (2016-2021) 5.2 Global End-Stage Kidney Disease Treatment Forecasted Market Size by Application (2022-2027) 6 North America 6.1 North America End-Stage Kidney Disease Treatment Market Size (2016-2027) 6.2 North America End-Stage Kidney Disease Treatment Market Size by Type 6.2.1 North America End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) 6.2.2 North America End-Stage Kidney Disease Treatment Market Size by Type (2022-2027) 6.2.3 North America End-Stage Kidney Disease Treatment Market Size by Type (2016-2027) 6.3 North America End-Stage Kidney Disease Treatment Market Size by Application 6.3.1 North America End-Stage Kidney Disease Treatment Market Size by Application (2016-2021) 6.3.2 North America End-Stage Kidney Disease Treatment Market Size by Application (2022-2027) 6.3.3 North America End-Stage Kidney Disease Treatment Market Size by Application (2016-2027) 6.4 North America End-Stage Kidney Disease Treatment Market Size by Country 6.4.1 North America End-Stage Kidney Disease Treatment Market Size by Country (2016-2021) 6.4.2 North America End-Stage Kidney Disease Treatment Market Size by Country (2022-2027) 6.4.3 United States 6.4.4 Canada 7 Europe 7.1 Europe End-Stage Kidney Disease Treatment Market Size (2016-2027) 7.2 Europe End-Stage Kidney Disease Treatment Market Size by Type 7.2.1 Europe End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) 7.2.2 Europe End-Stage Kidney Disease Treatment Market Size by Type (2022-2027) 7.2.3 Europe End-Stage Kidney Disease Treatment Market Size by Type (2016-2027) 7.3 Europe End-Stage Kidney Disease Treatment Market Size by Application 7.3.1 Europe End-Stage Kidney Disease Treatment Market Size by Application (2016-2021) 7.3.2 Europe End-Stage Kidney Disease Treatment Market Size by Application (2022-2027) 7.3.3 Europe End-Stage Kidney Disease Treatment Market Size by Application (2016-2027) 7.4 Europe End-Stage Kidney Disease Treatment Market Size by Country 7.4.1 Europe End-Stage Kidney Disease Treatment Market Size by Country (2016-2021) 7.4.2 Europe End-Stage Kidney Disease Treatment Market Size by Country (2022-2027) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic 8 Asia-Pacific 8.1 Asia-Pacific End-Stage Kidney Disease Treatment Market Size (2016-2027) 8.2 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Type 8.2.1 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) 8.2.2 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Type (2022-2027) 8.2.3 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Type (2016-2027) 8.3 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Application 8.3.1 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Application (2016-2021) 8.3.2 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Application (2022-2027) 8.3.3 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Application (2016-2027) 8.4 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Region 8.4.1 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Region (2016-2021) 8.4.2 Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Region (2022-2027) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America End-Stage Kidney Disease Treatment Market Size (2016-2027) 9.2 Latin America End-Stage Kidney Disease Treatment Market Size by Type 9.2.1 Latin America End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) 9.2.2 Latin America End-Stage Kidney Disease Treatment Market Size by Type (2022-2027) 9.2.3 Latin America End-Stage Kidney Disease Treatment Market Size by Type (2016-2027) 9.3 Latin America End-Stage Kidney Disease Treatment Market Size by Application 9.3.1 Latin America End-Stage Kidney Disease Treatment Market Size by Application (2016-2021) 9.3.2 Latin America End-Stage Kidney Disease Treatment Market Size by Application (2022-2027) 9.3.3 Latin America End-Stage Kidney Disease Treatment Market Size by Application (2016-2027) 9.4 Latin America End-Stage Kidney Disease Treatment Market Size by Country 9.4.1 Latin America End-Stage Kidney Disease Treatment Market Size by Country (2016-2021) 9.4.2 Latin America End-Stage Kidney Disease Treatment Market Size by Country (2022-2027) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa End-Stage Kidney Disease Treatment Market Size (2016-2027) 10.2 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Type 10.2.1 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) 10.2.2 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Type (2022-2027) 10.2.3 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Type (2016-2027) 10.3 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Application 10.3.1 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Application (2016-2021) 10.3.2 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Application (2022-2027) 10.3.3 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Application (2016-2027) 10.4 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Country 10.4.1 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Country (2016-2021) 10.4.2 Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Country (2022-2027) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 BLR Bio LLC 11.1.1 BLR Bio LLC Company Details 11.1.2 BLR Bio LLC Business Overview 11.1.3 BLR Bio LLC End-Stage Kidney Disease Treatment Introduction 11.1.4 BLR Bio LLC Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) 11.1.5 BLR Bio LLC Recent Development 11.2 CTI BioPharma Corp 11.2.1 CTI BioPharma Corp Company Details 11.2.2 CTI BioPharma Corp Business Overview 11.2.3 CTI BioPharma Corp End-Stage Kidney Disease Treatment Introduction 11.2.4 CTI BioPharma Corp Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) 11.2.5 CTI BioPharma Corp Recent Development 11.3 F. Hoffmann-La Roche Ltd 11.3.1 F. Hoffmann-La Roche Ltd Company Details 11.3.2 F. Hoffmann-La Roche Ltd Business Overview 11.3.3 F. Hoffmann-La Roche Ltd End-Stage Kidney Disease Treatment Introduction 11.3.4 F. Hoffmann-La Roche Ltd Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) 11.3.5 F. Hoffmann-La Roche Ltd Recent Development 11.4 Novartis AG 11.4.1 Novartis AG Company Details 11.4.2 Novartis AG Business Overview 11.4.3 Novartis AG End-Stage Kidney Disease Treatment Introduction 11.4.4 Novartis AG Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) 11.4.5 Novartis AG Recent Development 11.5 Prolong Pharmaceuticals LLC 11.5.1 Prolong Pharmaceuticals LLC Company Details 11.5.2 Prolong Pharmaceuticals LLC Business Overview 11.5.3 Prolong Pharmaceuticals LLC End-Stage Kidney Disease Treatment Introduction 11.5.4 Prolong Pharmaceuticals LLC Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) 11.5.5 Prolong Pharmaceuticals LLC Recent Development 11.6 VESSL Therapeutics Ltd 11.6.1 VESSL Therapeutics Ltd Company Details 11.6.2 VESSL Therapeutics Ltd Business Overview 11.6.3 VESSL Therapeutics Ltd End-Stage Kidney Disease Treatment Introduction 11.6.4 VESSL Therapeutics Ltd Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) 11.6.5 VESSL Therapeutics Ltd Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global End-Stage Kidney Disease Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027 Table 2. Key Players of MK-3866 Table 3. Key Players of Pacritinib Table 4. Key Players of Sanguinate Table 5. Key Players of Tesidolumab Table 6. Key Players of Others Table 7. Global End-Stage Kidney Disease Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027 Table 8. Global End-Stage Kidney Disease Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027 Table 9. Global End-Stage Kidney Disease Treatment Market Size by Regions (2016-2021) & (US$ Million) Table 10. Global End-Stage Kidney Disease Treatment Market Share by Regions (2016-2021) Table 11. Global End-Stage Kidney Disease Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million) Table 12. Global End-Stage Kidney Disease Treatment Market Share by Regions (2022-2027) Table 13. End-Stage Kidney Disease Treatment Market Trends Table 14. End-Stage Kidney Disease Treatment Market Drivers Table 15. End-Stage Kidney Disease Treatment Market Challenges Table 16. End-Stage Kidney Disease Treatment Market Restraints Table 17. Global End-Stage Kidney Disease Treatment Revenue by Players (2016-2021) & (US$ Million) Table 18. Global End-Stage Kidney Disease Treatment Market Share by Players (2016-2021) Table 19. Global Top End-Stage Kidney Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in End-Stage Kidney Disease Treatment as of 2020) Table 20. Ranking of Global Top End-Stage Kidney Disease Treatment Companies by Revenue (US$ Million) in 2020 Table 21. Global 5 Largest Players Market Share by End-Stage Kidney Disease Treatment Revenue (CR5 and HHI) & (2016-2021) Table 22. Key Players Headquarters and Area Served Table 23. Key Players End-Stage Kidney Disease Treatment Product Solution and Service Table 24. Date of Enter into End-Stage Kidney Disease Treatment Market Table 25. Mergers & Acquisitions, Expansion Plans Table 26. Global End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million) Table 27. Global End-Stage Kidney Disease Treatment Revenue Market Share by Type (2016-2021) Table 28. Global End-Stage Kidney Disease Treatment Forecasted Market Size by Type (2022-2027) (US$ Million) Table 29. Global End-Stage Kidney Disease Treatment Revenue Market Share by Type (2022-2027) & (US$ Million) Table 30. Global End-Stage Kidney Disease Treatment Market Size Share by Application (2016-2021) & (US$ Million) Table 31. Global End-Stage Kidney Disease Treatment Revenue Market Share by Application (2016-2021) Table 32. Global End-Stage Kidney Disease Treatment Forecasted Market Size by Application (2022-2027) (US$ Million) Table 33. Global End-Stage Kidney Disease Treatment Revenue Market Share by Application (2022-2027) & (US$ Million) Table 34. North America End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million) Table 35. North America End-Stage Kidney Disease Treatment Market Size by Type (2022-2027) & (US$ Million) Table 36. North America End-Stage Kidney Disease Treatment Market Size by Application (2016-2021) (US$ Million) Table 37. North America End-Stage Kidney Disease Treatment Market Size by Application (2022-2027) & (US$ Million) Table 38. North America End-Stage Kidney Disease Treatment Market Size by Country (2016-2021) & (US$ Million) Table 39. North America End-Stage Kidney Disease Treatment Market Size by Country (2022-2027) & (US$ Million) Table 40. Europe End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million) Table 41. Europe End-Stage Kidney Disease Treatment Market Size by Type (2022-2027) & (US$ Million) Table 42. Europe End-Stage Kidney Disease Treatment Market Size by Application (2016-2021) (US$ Million) Table 43. Europe End-Stage Kidney Disease Treatment Market Size by Application (2022-2027) & (US$ Million) Table 44. Europe End-Stage Kidney Disease Treatment Market Size by Country (2016-2021) & (US$ Million) Table 45. Europe End-Stage Kidney Disease Treatment Market Size by Country (2022-2027) & (US$ Million) Table 46. Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million) Table 47. Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Type (2022-2027) & (US$ Million) Table 48. Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Application (2016-2021) (US$ Million) Table 49. Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Application (2022-2027) & (US$ Million) Table 50. Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Region (2016-2021) & (US$ Million) Table 51. Asia-Pacific End-Stage Kidney Disease Treatment Market Size by Region (2022-2027) & (US$ Million) Table 52. Latin America End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million) Table 53. Latin America End-Stage Kidney Disease Treatment Market Size by Type (2022-2027) & (US$ Million) Table 54. Latin America End-Stage Kidney Disease Treatment Market Size by Application (2016-2021) (US$ Million) Table 55. Latin America End-Stage Kidney Disease Treatment Market Size by Application (2022-2027) & (US$ Million) Table 56. Latin America End-Stage Kidney Disease Treatment Market Size by Country (2016-2021) & (US$ Million) Table 57. Latin America End-Stage Kidney Disease Treatment Market Size by Country (2022-2027) & (US$ Million) Table 58. Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Type (2016-2021) (US$ Million) Table 59. Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Type (2022-2027) & (US$ Million) Table 60. Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Application (2016-2021) (US$ Million) Table 61. Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Application (2022-2027) & (US$ Million) Table 62. Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Country (2016-2021) & (US$ Million) Table 63. Middle East & Africa End-Stage Kidney Disease Treatment Market Size by Country (2022-2027) & (US$ Million) Table 64. BLR Bio LLC Company Details Table 65. BLR Bio LLC Business Overview Table 66. BLR Bio LLC End-Stage Kidney Disease Treatment Product Table 67. BLR Bio LLC Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) & (US$ Million) Table 68. BLR Bio LLC Recent Development Table 69. CTI BioPharma Corp Company Details Table 70. CTI BioPharma Corp Business Overview Table 71. CTI BioPharma Corp End-Stage Kidney Disease Treatment Product Table 72. CTI BioPharma Corp Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) & (US$ Million) Table 73. CTI BioPharma Corp Recent Development Table 74. F. Hoffmann-La Roche Ltd Company Details Table 75. F. Hoffmann-La Roche Ltd Business Overview Table 76. F. Hoffmann-La Roche Ltd End-Stage Kidney Disease Treatment Product Table 77. F. Hoffmann-La Roche Ltd Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) & (US$ Million) Table 78. F. Hoffmann-La Roche Ltd Recent Development Table 79. Novartis AG Company Details Table 80. Novartis AG Business Overview Table 81. Novartis AG End-Stage Kidney Disease Treatment Product Table 82. Novartis AG Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) & (US$ Million) Table 83. Novartis AG Recent Development Table 84. Prolong Pharmaceuticals LLC Company Details Table 85. Prolong Pharmaceuticals LLC Business Overview Table 86. Prolong Pharmaceuticals LLC End-Stage Kidney Disease Treatment Product Table 87. Prolong Pharmaceuticals LLC Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) & (US$ Million) Table 88. Prolong Pharmaceuticals LLC Recent Development Table 89. VESSL Therapeutics Ltd Company Details Table 90. VESSL Therapeutics Ltd Business Overview Table 91. VESSL Therapeutics Ltd End-Stage Kidney Disease Treatment Product Table 92. VESSL Therapeutics Ltd Revenue in End-Stage Kidney Disease Treatment Business (2016-2021) & (US$ Million) Table 93. VESSL Therapeutics Ltd Recent Development Table 94. Research Programs/Design for This Report Table 95. Key Data Information from Secondary Sources Table 96. Key Data Information from Primary Sources List of Figures Figure 1. Global End-Stage Kidney Disease Treatment Market Share by Type: 2020 VS 2027 Figure 2. MK-3866 Features Figure 3. Pacritinib Features Figure 4. Sanguinate Features Figure 5. Tesidolumab Features Figure 6. Others Features Figure 7. Global End-Stage Kidney Disease Treatment Market Share by Application: 2020 VS 2027 Figure 8. Clinic Case Studies Figure 9. Hospital Case Studies Figure 10. Others Case Studies Figure 11. End-Stage Kidney Disease Treatment Report Years Considered Figure 12. Global End-Stage Kidney Disease Treatment Market Size (US$ Million), Year-over-Year: 2016-2027 Figure 13. Global End-Stage Kidney Disease Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027 Figure 14. Global End-Stage Kidney Disease Treatment Market Share by Regions: 2020 VS 2027 Figure 15. Global End-Stage Kidney Disease Treatment Market Share by Regions (2022-2027) Figure 16. Global End-Stage Kidney Disease Treatment Market Share by Players in 2020 Figure 17. Global Top End-Stage Kidney Disease Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in End-Stage Kidney Disease Treatment as of 2020 Figure 18. The Top 10 and 5 Players Market Share by End-Stage Kidney Disease Treatment Revenue in 2020 Figure 19. Global End-Stage Kidney Disease Treatment Revenue Market Share by Type (2016-2021) Figure 20. Global End-Stage Kidney Disease Treatment Revenue Market Share by Type (2022-2027) Figure 21. North America End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 22. North America End-Stage Kidney Disease Treatment Market Share by Type (2016-2027) Figure 23. North America End-Stage Kidney Disease Treatment Market Share by Application (2016-2027) Figure 24. North America End-Stage Kidney Disease Treatment Market Share by Country (2016-2027) Figure 25. United States End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 26. Canada End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 27. Europe End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 28. Europe End-Stage Kidney Disease Treatment Market Share by Type (2016-2027) Figure 29. Europe End-Stage Kidney Disease Treatment Market Share by Application (2016-2027) Figure 30. Europe End-Stage Kidney Disease Treatment Market Share by Country (2016-2027) Figure 31. Germany End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 32. France End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 33. U.K. End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 34. Italy End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 35. Russia End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 36. Nordic End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 37. Asia-Pacific End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 38. Asia-Pacific End-Stage Kidney Disease Treatment Market Share by Type (2016-2027) Figure 39. Asia-Pacific End-Stage Kidney Disease Treatment Market Share by Application (2016-2027) Figure 40. Asia-Pacific End-Stage Kidney Disease Treatment Market Share by Region (2016-2027) Figure 41. China End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 42. Japan End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 43. South Korea End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 44. Southeast Asia End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 45. India End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 46. Australia End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 47. Latin America End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 48. Latin America End-Stage Kidney Disease Treatment Market Share by Type (2016-2027) Figure 49. Latin America End-Stage Kidney Disease Treatment Market Share by Application (2016-2027) Figure 50. Latin America End-Stage Kidney Disease Treatment Market Share by Country (2016-2027) Figure 51. Mexico End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 52. Brazil End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 53. Middle East & Africa End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 54. Middle East & Africa End-Stage Kidney Disease Treatment Market Share by Type (2016-2027) Figure 55. Middle East & Africa End-Stage Kidney Disease Treatment Market Share by Application (2016-2027) Figure 56. Middle East & Africa End-Stage Kidney Disease Treatment Market Share by Country (2016-2027) Figure 57. Turkey End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 58. Saudi Arabia End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 59. UAE End-Stage Kidney Disease Treatment Market Size YoY Growth (2016-2027) & (US$ Million) Figure 60. BLR Bio LLC Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2016-2021) Figure 61. CTI BioPharma Corp Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2016-2021) Figure 62. F. Hoffmann-La Roche Ltd Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2016-2021) Figure 63. Novartis AG Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2016-2021) Figure 64. Prolong Pharmaceuticals LLC Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2016-2021) Figure 65. VESSL Therapeutics Ltd Revenue Growth Rate in End-Stage Kidney Disease Treatment Business (2016-2021) Figure 66. Bottom-up and Top-down Approaches for This Report Figure 67. Data Triangulation Figure 68. Key Executives Interviewed

BLR Bio LLC CTI BioPharma Corp F. Hoffmann-La Roche Ltd Novartis AG Prolong Pharmaceuticals LLC VESSL Therapeutics Ltd